BFS
TARS icon

Bare Financial Services’s Tarsus Pharmaceuticals TARS Stock Holding History

Bare Financial Services’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13
Closed -$912 – 1912
2026
Q1 		$912 Buy
13
+7
+117% +$489 ﹤0.01% 1291
2025
Q4 		$491 Buy
+6
New +$448 ﹤0.01% 1418

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bare Financial Services's TARS Position: Q2 2026 in Review

Bare Financial Services sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 13 shares — an estimated $912 sold.

Bare Financial Services first reported a position in TARS in Q4 2025 and held it in 2 quarters. The position peaked at $912 in Q1 2026. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Bare Financial Services reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bare Financial Services sold 13 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $912.
  • Bare Financial Services first reported a position in Tarsus Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Bare Financial Services's Tarsus Pharmaceuticals position peaked at $912 in Q1 2026.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.